

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Honliv Healthcare Management Group Company Limited

宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of Company dated 22 August 2022 (the “**Announcement**”) in relation to the adoption of the 2022 restricted share unit scheme. Unless otherwise specified, capitalized terms used herein shall have the same meaning as those defined in the Announcement.

The Company would like to clarify that there are inadvertent typographical errors in the section headed “IV. Maximum Limit” on page 2 of the Announcement. The first line of that section should read as follows (with the corrected numbers underlined):

The aggregate amount of existing Shares to be purchased by the Trustee under the Scheme shall not exceed 5% of the Company’s total issued share capital as of the Adoption Date (being no more than 30,000,000 Shares).

Save as disclosed in this announcement, all information set out in the Announcement remain unchanged.

By order of the Board
Honliv Healthcare Management Group Company Limited
Mr. Qin Yan
Chairman

Hong Kong, 23 August 2022

As at the date of this announcement, the Board comprises Mr. Qin Yan, Dr. Teng Qingxiao and Mr. Wang Zhongtao as the executive Directors, Mr. Qin Hongchao as the non-executive Director and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive Directors.